THERADIAG notes the acquisition of a stake in its capital by BIOSYNEX
November 30 2021 - 1:30AM
Business Wire
Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker:
ALTER), a company specializing in in vitro diagnostics and
Theranostics, today announces that it has received yesterday a
letter from BIOSYNEX informing it of its acquisition of a stake in
its capital and the crossing of statutory thresholds, in accordance
with article 12.3 of THERADIAG's articles of association.
Following acquisitions on the market and its participation in
the Rights Issue, BIOSYNEX held 2,468,932 shares, i.e. 18.82% of
THERADIAG's share capital and 18.89% of its voting rights, as at 29
November 2021 at 8:00 a.m.
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing, and marketing
innovative in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2020, the Company posted revenue of €10.4 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
https://www.theradiag.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211129005813/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent Quentin Massé Tel.: +33 (0)1 44 71 94
94 theradiag@newcap.eu NewCap Media Relations Nicolas
Mérigeau Tel.: +33 (0)1 44 71 94 98 nmerigeau@newcap.fr
Theradiag (EU:ALTER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Theradiag (EU:ALTER)
Historical Stock Chart
From Apr 2023 to Apr 2024
